ng28ÄϹ¬Öêʽ»áÉ磨×ܲ¿£º¶«¾©£¬Ê×ϯִÐй٣ºÄÚÌÙÇç·ò£¬ÏÂÎļò³Æ¡°ng28ÄϹ¬¡±£©½üÈÕÐû²¼£¬ng28ÄϹ¬ÒÑÓëRoivant Sciences Ltd.£¨ÄÉ˹´ï¿Ë¹ÉƱ´úÂ룺ROIV£¬×ܲ¿£ºÓ¢¹úÂ׶أ¬ÏÂÎļò³Æ¡°Roivant¡±£©µÄÒ»¼Ò×Ó¹«Ë¾Ç©¶©Ðí¿ÉÐÒ飬¶À¼ÒÊÚÓèRoivantÊÔÑéÐÔ¿¹°©Ò©H3B-8800µÄÈ«ÇòÑо¿¡¢¿ª·¢¡¢Éú²úºÍÏúÊÛȨ¡£H3B-8800£¨Roivant¿ª·¢´úÂ룺RVT-2001£©ÊÇÒ»ÖÖ¼ô½Óµ÷Àí¼Á»¯ºÏÎÓÉng28ÄϹ¬µÄÃÀ¹úÑз¢×Ó¹«Ë¾H3 Biomedicine Inc.·¢Ã÷£¬Ä¿Ç°ÕýÔÚ×÷ΪÊÔÑéÐÔ¿¹°©Ò©½øÐпª·¢¡£
H3B-8800ÊÇÒ»ÖÖ¿Ú·þ¿ÉÀûÓõļô½ÓÒò×Ó3BÑÇ»ù1£¨SF3B1£©µÄС·Ö×Óµ÷Àí¼Á£¬ÓÉH3 Biomedicine Inc.·¢Ã÷¡£ÔÚ»ùÓÚÒÅ´«ÃÜÂëµÄÂÑ°×ÖʺϳÉÀú³ÌÖУ¬¼ô½Ó¿ÉÈ¥³ýÂÑ°×Öʺϳɲ»ÐèÒªµÄÐÅʹǰÌåRNA£¨mRNA£©¼î»ùÐòÁеÄÄÚº¬×Ó¡£ÔÚ¶àÖÖ¶ñÐÔѪҺ²¡ºÍʵÌåÁöÖоù¿ÉÊӲ쵽±àÂë¼ô½ÓÒò×ӵĻùÒòÍ»±ä¡£SF3B1ÊÇÌر𳣼ûµÄ¼ô½ÓÒò×Ó»ùÒòÍ»±ä¡£1,2H3B-8800¿É½áºÏSF3B1£¬²¢Í¨¹ýÏû³ý¶Ô°©Ö¢»¼ÕßmRNA¼ô½ÓµÄÆÆ»µ£¬ÔÚÁÙ´²Ç°Ä£ÐÍÖÐÌåÏÖ³öÃ÷ÏԵĿ¹Ö×Áö»îÐÔ¡£3ng28ÄϹ¬ºÍH3 BiomedicineÄ¿Ç°ÕýÔÚÃÀ¹úºÍÅ·ÖÞ¶ÔЯ´øSF3B1Í»±äµÄ¹ÇËèÒì³£ÔöÉú×ÛºÏÕ÷»¼Õß¿ªÕ¹Ò»ÏîH3B-8800µÄIÆÚÁÙ´²ÊÔÑé¡£
ƾ¾ÝÐÒéÌõ¿î£¬ng28ÄϹ¬½«»ñµÃH3B-8800µÄÌõÔ¼Ô¤¸¶¿î¡¢¿ª·¢ºÍ×¢²áÀï³Ì±®¸¶¿î£¬ÉÏÊк󻹽«Æ¾¾ÝH3B-8800µÄÏúÊÛÊÕÈ룬»ñµÃÌض¨±ÈÀýµÄÌØÐíȨʹÓ÷ѡ£
RoivantÊÇÒ»¸ö¾ßÓÐÆæÌØÉÌҵģʽµÄÉúÎïÖÆÒ©¹«Ë¾¡£Roivant½¨Á¢²¢ÌᳫÁ˶à¼Ò×Ó¹«Ë¾£¬ºÏ³ÆΪ¡°Vants¡±£¬ÔÚ²î±ðµÄÖÎÁÆÁìÓò½øÐиßЧµÄÁÙ´²¿ª·¢ÊÂÇé¡£ng28ÄϹ¬ÈÏΪ£¬ÓëRoivantÇ©ÊðµÄ±¾Ðí¿ÉÐÒ齫ÓÐÖúÓÚÍƶ¯H3B-8800µÄ¼ÛÖµ×î´ó»¯¡£ng28ÄϹ¬½«¼ÌÐø¼ÓËÙÆä»ùÓÚÇ°ÑØ°©Ö¢Ñо¿µÄÐÂÒ©·¢Ã÷£¬½ßÁ¦½â¾ö°©Ö¢»¼Õß¡¢»¼Õß¼ÒÍ¥ºÍÒ½ÁÆЧÀÍÌṩÕßµÄÖÖÖÖÐèÇó²¢Ôö¼ÓÆä»ñÒæ¡£
ÁªÏµ·½·¨£º
ng28ÄϹ¬Öêʽ»áÉç
¹«¹²¹Øϵ²¿
+81-(0)3-3817-5120
[±àÕß×¢]
1.¹ØÓÚH3 Biomedicine, Inc.
H3 Biomedicine, Inc.ÊÇÒ»¼Ò×ܲ¿Î»ÓÚÂíÈøÖîÈûÖݽ£ÇŵÄÉúÎïÖÆÒ©¹«Ë¾£¬×¨×¢ÓÚÀûÓÃÆ伯³ÉÊý¾Ý¿Æѧ¡¢ÈËÀàÉúÎïѧºÍ¾«×¼»¯Ñ§·¢Ã÷ÒýÇ棬·¢Ã÷ºÍ¿ª·¢¾«×¼Ö×ÁöÖÎÁÆÒªÁ죬ÖÂÁ¦ÓÚ¸ÄÉÆ»¼ÕßÉú»î¡£¸Ã¹«Ë¾½¨Á¢ÓÚ2010Äê12Ô£¬ÊÇng28ÄϹ¬ÃÀ¹úÖÆÒ©¹«Ë¾Eisai Inc.µÄ×Ó¹«Ë¾¡£H3 BiomedicineÓëng28ÄϹ¬Öêʽ»áÉçÏàÖú£¬×¨×¢ÓÚÆä¹ÜÏß²úÆ·µÄÁ¬Ðøºã¾Ã½»¸¶£¬ng28ÄϹ¬Öêʽ»áÉçÂôÁ¦ÌṩÐëÒªµÄÑо¿×ʽðÒÔ¼°È«Çò»¯ÖÆÒ©¹«Ë¾µÄ¹¦Ð§ºÍ×ÊÔ´¡£
ÓûÁ˽â¸ü¶àÐÅÏ¢£¬Çë»á¼ûwww.h3biomedicine.com¡£
2.¹ØÓÚRoivant
RoivantµÄʹÃüÊÇͨ¹ýÂò½øÒòÖÖÖÖÒòËر»ÊøÖ®¸ß¸óµ«ÈÔ¾ßÓпª·¢Ç±Á¦µÄºòÑ¡Ò©Î²¢½øÐмÓËÙ¿ª·¢£¬¸ÄÉÆÏò»¼ÕßÌṩµÄÒ½ÁƱ£½¡²úÆ·¡£Roivantͨ¹ý´´Á¢ÐԵع¹½¨¼¼ÊõºÍ¿ª·¢È˲ţ¬ÀûÓÃRoivantƽ̨ÍƳöVants¡ª¡ª¶à¼ÒÁé»îÇÒרעµÄÉúÎïÖÆÒ©ºÍÒ½ÁƼ¼Êõ¹«Ë¾£¬´Ó¶ø¸ü¿ìµØ¿ª·¢ÐÂÐÍÒ©Îï¡£
ÓûÁ˽â¸ü¶àÐÅÏ¢£¬Çë»á¼ûwww.roivant.com¡£
1 Yoshida, et al. (2011). Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 478(7367): 64-69. doi: 10.1038/nature10496.
2 Seiler, et al. (2018). Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports 23(1): 282-296.e4. doi: 10.1016/j.celrep.2018.01.088.
3 Seiler, et al. (2018). H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. Nature Medicine 24(4): 497-504. doi: 10.1038/nm.4493.